MedTrace Logo

Study of Real Clinical Practice to Evaluate the Effects of Oral Dydrogesterone for Treatment of Confirmed Endometriosis

NCT03690765 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2021-12-28

No results posted yet for this study

Summary

A non-interventional, observational program to assess the effects of dydrogesterone (Duphaston®) 6-months-administration in patients with confirmed endometriosis in a post-marketing setting in the Russian Federation

Conditions

  • Endometriosis

Interventions

DRUG

Duphaston® (Dydrogesterone)

No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle. Description of routine practice only.

DRUG

Duphaston® (Dydrogesterone)

No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day continuously. Description of routine practice only.

Sponsors & Collaborators

Principal Investigators

  • Andrey V Kozachenko, Prof · Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-27
Primary Completion
2019-11-10
Completion
2020-05-29

Countries

  • Russia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03690765 on ClinicalTrials.gov